spacer
home > ebr > winter 2018 > particle acceleration
PUBLICATIONS
European Biopharmaceutical Review

Particle Acceleration

First established more than 200 years ago as a defence against infectious diseases, vaccine development proliferated in the mid-20th century as researchers began to fully exploit the use of inactive and attenuated disease strains. The key to a successful vaccine is to identify and isolate an agent that can be safely administered to the patient to trigger a sufficiently protective immune response, without causing a full-blown illness. For some diseases, a completely inactive strain performs this function, while for others attenuation or modification of an active strain – often by passaging through animal embryos – provides an answer.

More recently, newer vaccine technologies have been adopted to tackle diseases not amenable to these traditional approaches. Today’s researchers routinely deploy subunit and conjugate vaccines – both of which contain only fractions of the pathogen for which they provide protection – and viruslike particles (VLPs). These ‘trick’ the body into an immune response by precisely mimicking the morphology and outer surface of the live virus, but lack the genetic material needed to reproduce, thereby offering the same levels of safety as inactive vaccines. In vivo, such VLPs must be effectively indistinguishable from the active pathogen, so their structure is critical.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Professor Dave Stuart is Medical Research Council Professor of structural biology at the University of Oxford, UK, and joint-head of the division of structural biology at the Department of Clinical Medicine. He was appointed Director of Life Sciences at Diamond Light Source in 2008. Dave’s principal research interests include the structure of viruses and viral proteins, as well as cellular proteins, especially those that interact with viruses.
spacer
Diamond Light Source
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT Webinar Will Discuss How to Optimize Microbiome Research

BioIVT, a leading provider of research models and services for drug development, today announced that it is hosting a webinar entitled “The Microbiome: Understanding Why Collection and Processing Matters” at 11 a.m. ET on July 25.
More info >>

White Papers

Unmet Medical Needs? Impacted by unmet Life Sciences Staffing Needs?

Clinical Professionals

Whilst the majority of Clinical Professionals clients are working to discover and develop innovative, cost effective medicines that address unmet medical needs they are not impacting the unmet needs of training and developing new recruits into the pharma industry. The impact is highlighted within entry level Clinical Trial Administrators and Clinical Research Associates (CTA/CRA). In the past the Pharmaceutical industry had highly developed training programs for these sought after candidates. As the use of outsourcing models and CRO’s has increased and fewer Pharma businesses embark on their own R&D a substantial gap is developing in newly trained Life Science graduates entering the market to commence a career within R&D. As further financial cuts are made within R&D spend this already dire situation continues to escalate.
More info >>

 
Industry Events

Clinical Trial Supply East coast 2018

16-17 October 2018, King of Prussia, PA

This unique event brings together leading pharma, device and biotech professionals from across the East Coast region, to collaboratively enhance the clinical supply chain. Over the two days, delegates and speakers will discuss how to select forecasting and planning technology, how to reduce waste in clinical trials supplies, how to choose your packaging strategy, but we will also discover all the new technologies that will disrupt your clinical trials supplies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement